<DOC>
	<DOCNO>NCT00601016</DOCNO>
	<brief_summary>Hemangiomas infancy , common benign tumor infancy , congenital early infancy lesion characterize rapid postnatal growth , high expression angiogenic stimulators 9-18 month , follow slow regression 5-9 year . Current therapy hemangiomas usually restrict severe form due risk adverse effect , inconvenience cost . Nevertheless , substantial amount psychological discomfort morbidity cause untreated hemangioma , especially face . Recently , Imiquimod 5 % cream emerge safe effective drug several skin condition benefit modulation activity immune system , common wart various form skin pre-cancerous cancerous lesion . Small case report series suggest could also useful hemangioma , possibly inhibition angiogenesis local IFN production.This small , open label study 16 patient document efficacy Imiquimod 5 % cream treatment hemangioma infancy ( primary outcome ) . IFN plasma drug level , well clinical examination blood study , carry evaluate safety treatment ( secondary outcome ) . bFGF VEGF measure blood urine order study diagnostic predictive value pro-angiogenic factor response hemangioma treatment Imiquimod ( secondary outcome ) . The study phase II clinical trial day application Imiquimod 5 % cream , 3 7 time per week maximum four month . The study hold Dermatology Clinic Sainte-Justine Hospital , complete within 20 month timeframe IRB approval .</brief_summary>
	<brief_title>A Phase II Study Imiquimod 5 % Cream Treatment Hemangioma Infancy</brief_title>
	<detailed_description />
	<mesh_term>Hemangioma</mesh_term>
	<mesh_term>Hemangioma , Capillary</mesh_term>
	<mesh_term>Port-Wine Stain</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Healthy infant age 212 month . Superficial mixed hemangioma proliferative phase ( grow size last 12 month ) . Hemangiomas must less 10X10 cm must ulcerate . Preterm infant ( le 36 week gestation ) . Ulceration hemangioma prior treatment . Immunosuppression . Hemangioma locate eyelid perianal region . Prior treatment hemangioma . Concomitant disease . Presence multiple hemangioma and/or hemangioma would require systemic drug treatment . Potential difficulty followup ( patient another town , difficult access hospital , etc. ) . History allergy component drug preparation . Hemangiomas 10X 10 cm ulcerated start treatment .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Infantile hemangioma</keyword>
	<keyword>Hemangioma</keyword>
	<keyword>Hemangioma Infancy</keyword>
	<keyword>benign tumor infancy</keyword>
	<keyword>Congenital hemangioma</keyword>
	<keyword>Capillary</keyword>
</DOC>